Seroprevalence of Trypanosoma cruzi infection among at‐risk blood donors in Japan

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2019-01, Vol.59 (1), p.287-294
• Main Authors: Sayama, Yusuke, Furui, Yasumi, Takakura, Akiko, Ishinoda, Masazumi, Matsumoto, Chieko, Taira, Rikizo, Igarashi, Shigeru, Momose, Shun'ya, Matsubayashi, Keiji, Uchida, Shigeharu, Hino, Satoru, Nagai, Tadashi, Satake, Masahiro
• Format: Article
• Language: English
• Subjects: Addition polymerization; Antibodies; Blood; Blood & organ donations; Blood donors; Blood transfusion; Chagas disease; Chemiluminescence; Deoxyribonucleic acid; Disease transmission; DNA; Enzymes; Health risks; Immigrants; Immunoassay; Immunoglobulins; Infections; Organic chemistry; Polymerase chain reaction; Protozoa; Risk; Serology; Transfusion; Trypanosoma cruzi; Vector-borne diseases
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.14999

BACKGROUND Chagas disease is caused by Trypanosoma cruzi and is endemic in Latin America. In nonendemic countries, including Japan, Chagas disease is primarily a problem in the context of transfusion transmission. Approximately 250,000 immigrants from Latin America reside in Japan, and many of those individuals serve as active blood donors. This study surveyed the seroprevalence of T. cruzi infection among at‐risk blood donors in Japan, defined as those who themselves (or whose mothers) were born (or raised) in Latin America, or those with a travel history to Latin America. STUDY DESIGN AND METHODS Blood samples were obtained from at‐risk donors in two periods, 2004–2012 and 2013–2016. Collected samples were tested for T. cruzi antibodies using both an enzyme‐linked immunosorbent assay and a chemiluminescent immunoassay. Samples that tested positive in both assays were additionally tested by polymerase chain reaction, and look‐back investigation was conducted when necessary. RESULTS Of 18,484 samples obtained from 18,076 at‐risk donors, 3 (1:6,025, 0.017%) donors showed seroreactivity by enzyme‐linked immunosorbent assay and chemiluminescent immunoassay. All antibody‐positive donors were born in Latin America. One of them also was positive for T. cruzi DNA. Eleven previous donations from this donor were subjected to look‐back investigation, and five recipients were tested. All five recipients tested negative for T. cruzi antibodies. CONCLUSION Seroprevalence of T. cruzi was 0.017% among at‐risk donors in Japan. Transfusion‐transmitted infection of Chagas disease has not been confirmed to date. Screening for T. cruzi antibodies by targeting at‐risk donors is an appropriate strategy for ensuring blood safety in Japan.